Apimeds Pharmaceuticals Delays Annual 10-K Filing

Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has released a notification of late filing.

Apimeds Pharmaceuticals US, Inc. has notified regulators that it will be late filing its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company submitted a Form 12b-25, confirming the delay applies to its annual report for the fourth quarter and full-year 2025.

The company attributes the delay mainly to the time required to finalize its financial statements for the fourth quarter and full year. Its independent registered public accounting firm also needs additional time to complete its review and audit of these financials, making an on-time filing impractical without unreasonable effort or expense.

Apimeds Pharmaceuticals US, Inc. has stated that it expects to file the 2025 Form 10-K (Yearly Report) within the standard fifteen-day grace period allowed under SEC Rule 12b-25. This indicates investors should anticipate the annual filing relatively soon after the original deadline, barring unforeseen complications.

The company does not anticipate any significant change in its results of operations compared with the prior fiscal year based on the information currently available. No preliminary financial results were released in this notice, and any expectations about future performance or timing remain forward-looking and subject to change.

Apimeds Pharmaceuticals US, Inc. also confirmed that all other required periodic reports over the past 12 months have been filed. The notification was signed on March 31, 2026, by Chief Financial Officer Erick Frim, underscoring management’s ongoing effort to remain compliant while completing the year-end reporting process.

More about Apimeds Pharmaceuticals US, Inc.

Average Trading Volume: 164,841

Technical Sentiment Signal: Hold

Current Market Cap: $22.01M

For an in-depth examination of APUS stock, go to TipRanks’ Overview page.